SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants sharp rally is being linked by traders to its Oracle collaboration and reported role in bank tokenized-deposit and interoperability projects, with low supply and potential institutional demand adding to bullish speculation. Others question whether those partnerships will create meaningful demand for the QNT token, while the rapid gains have prompted volatile profit-taking and pullbacks.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 extension data presented at the World Muscle Society showed slower upper-limb function decline among patients who switched to deramiocel, fueling a sharp rally and renewed optimism about the Duchenne treatment. Many traders view the results as strengthening the case for FDA approval, while others argue the data may not resolve the agencys concerns over the trials analysis and the outcome remains uncertain.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher 2026 revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is the main catalyst behind the sharp share-price jump. Traders largely view the update as validation of the commercial ramp, while short-squeeze speculation and anticipation of lung-cancer data add to the enthusiasm; others caution that the stock may be overbought or face dilution risk.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Attention centers on MoonLakes anticipated BLA filing for sonelokimab in hidradenitis suppurativa, with traders watching for the filing and potential supporting adolescent data. The discussion is split between hopes that regulatory progress could restore confidence and concerns about the prior share sale, disappointing PsA data, managements commercialization plans, and the risk of filing or execution setbacks.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO shares are under pressure after FHFA changes put VantageScore alongside FICO in the mortgage-pricing framework, raising concerns that lenders could shift away from FICO and erode its pricing power and mortgage-scoring moat. Traders are split between expecting sustained competitive pressure and viewing the selloff as an overreaction because adoption is not guaranteed and FICO remains established with lenders.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda is drawing attention after Hetlioz met its Phase 3 endpoint in a trial for delayed sleep-wake phase disorder, with the company planning to discuss an additional FDA indication. Traders largely welcomed the result and speculated about commercial upside or a possible buyout, while some noted the small trial and that FDA approval is still pending.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuums finalized federal CHIPS R&D award is drawing attention as a sign of U.S. government backing for its quantum-computing development. Bulls view the support as validation, while skeptics point to the companys high valuation, limited revenue and volatile trading.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

A strong quarterly report and upbeat growth outlook have fueled a sharp rally, with traders pointing to market-share gains and accelerating ad-tech growth. The debate is whether momentum can continue or the stock will pull back after its volatile post-earnings run.

GEOM maps the world's oil fields, mines, rare earths, and power plants, tracks what is and isn't tokenized, and cryptographically signs every dataset it publishes. Anyone can verify what we said and when. No account, no key, no permission. Sources include the WRI Global Power Plant Database and Global Energy Monitor (CC BY 4.0), attributed in full inside the app. Most of it already exists, spread across filings and terminals no one reads. GEOM gathers it and records where each figure came from.

GEOM

Traders are focused on GEOMs proposed platform for tokenizing oil and mineral assets and royalties, with bullish discussion linking it to Greenland-related projects and an anticipated platform demo or launch. The thesis remains speculative, and the community is divided between accumulation hopes and concerns about thin liquidity, unverified adoption, and sharp pullbacks.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention amid a sharp move higher and enthusiasm around Zebecs payroll and payments expansion, including its MoneyGram connectivity and enterprise payroll activity on Stellar. Traders are also circulating Robinhood and BlackRock speculation, but those claims are unconfirmed; some remain skeptical that partnerships and adoption will translate into sustained token demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


1winjapan

1win Japan